COMPASS Pathways Plc - American Depository Shares (CMPS)

Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval.

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

The company is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty investor expectations.

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid investor disappointment

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.